ReviewJournal of personalized medicine2023
Combination of Biological Therapy in Severe Asthma: Where We Are?
Review in Journal of personalized medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Impact of IL-4/IL-13 Blockade with Dupilumab on the Microbiome in Type 2 Inflammatory Diseases: A Systematic Review.Current allergy and asthma reports · 2026Pooled it
- Incidence of New Malignancies in Severe Asthma: Comparison of Real-World Patients Treated with Benralizumab, Other Biologics, or Non-biologics.Pulmonary therapy · 2026Article
- Estrogen receptor β regulates sex-dependent airway mechanics and inflammation in a murine model of allergen exposure.Physiological reports · 2026Article
- Beyond Triple Therapy: Anti-Type 2 Biologic Therapies for Eosinophilic COPD and Respiratory Comorbidities - a Review of Clinical Evidence.Current allergy and asthma reports · 2026Review
- Impact of Dupilumab on Small Airway Disease in Severe Asthma: A 12-Month Retrospective Real-World Study.Advances in respiratory medicine · 2026Article
- Most Promising Emerging Therapies for Pulmonary Fibrosis: Targeting Novel Pathways.Biomedicines · 2026Review
- Age-specific efficacy of biologics in severe asthma: a pediatric perspective.Frontiers in allergy · 2026Review
- Asthma in Patients With Confirmed Pulmonary Sarcoidosis.Canadian respiratory journal · 2026Review
- Exploring type 2 inflammation and disease complexity: perspectives of a clinical immunologist.Frontiers in immunology · 2026Review
- Biologic Therapies for Severe Asthma: Current Insights and Future Directions.Journal of clinical medicine · 2025Review
- Is There a Place for Cannabinoids in Asthma Treatment?International journal of molecular sciences · 2025Review
- Combining Dual Biologics Therapy for Severe Asthma: A Series of Ten Cases.Journal of asthma and allergy · 2025Article
- Biologics in severe asthma: a state-of-the-art review.European respiratory review : an official journal of the European Respiratory Society · 2025Review
- Inflammatory and homeostatic roles of eosinophil subpopulations in chronic rhinosinusitis with nasal polyp pathogenesis.Frontiers in immunology · 2025Review
- Biologic therapy in rare eosinophil-associated disorders: remaining questions and translational research opportunities.Journal of leukocyte biology · 2024Review
- Dual blockade of IL-17A and IL-36 pathways via a bispecific antibody exhibits enhanced anti-inflammatory potency.Frontiers in immunology · 2024Article
- Personalized Medicine in Severe Asthma: From Biomarkers to Biologics.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biological drugs have revolutionized the management of severe asthma. However, a variable number of patients remain uncontrolled or only partially controlled even after the appropriate administration of a biologic agent. The combination of two biologics may target different inflammatory pathways, and it has been used in patients suffering from uncontrolled severe asthma with evidence of both allergic and eosinophilic phenotypes or severe asthma and type2 comorbidities. Combination therapy has also been used to handle anti-IL4/13R induced hypereosinophilia. There is insufficient data on combining biologics for the treatment of severe uncontrolled asthma and type 2 comorbidities, also because of the high cost, and currently no guideline recommends dual biologic therapy. A systematic search was performed using the Medline and Scopus databases. Published data on concurrent administration of two biological drugs in severe, uncontrolled asthma patients has been reported in 28 real-world studies and 1 clinical trial. Data extraction was followed by a descriptive and narrative synthesis of the findings. Future studies should be conducted to further assess the safety, efficacy, and cost-effectiveness of this therapeutic strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.